Confirmatory Study of DSP-5423P in Patients With Schizophrenia
Phase of Trial: Phase III
Latest Information Update: 14 Feb 2018
At a glance
- Drugs Blonanserin (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Sponsors Sumitomo Dainippon Pharma
- 14 Feb 2018 According to a Sumitomo Dainippon Pharma media release,company intends to submit an application for manufacturing and marketing approval of blonanserin in Japan during the first half of 2018.
- 14 Feb 2018 According to a Sumitomo Dainippon Pharma media release, primary endpoint (Change in PANSS total score from baseline) has been met.
- 14 Feb 2018 Topline results presented in a Sumitomo Dainippon Pharma Media Release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History